The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis
Open accessAbstract
We sought to study whether the better pharmacokinetic and pharmacodynamic (PK/PD) properties of carbapenems and piperacillin/tazobactam, when the duration of infusion is longer, were associated with lower mortality. PubMed and Scopus were searched for studies reporting on patients treated with extended (≥3 hours) or continuous (24 hours) versus short-term duration (20-60 minutes) infusions of carbapenems or piperacillin/tazobactam. Fourteen studies were included (1229 patients). Mortality was lower among patients receiving extended or continuous infusion of carbapenems or piperacillin/tazobactam compared to those receiving short-term (risk ratio [RR], 0.59; 95% confidence interval [CI], .41-.83). Patients with pneumonia who received extended or continuous infusion had lower mortality than those receiving short-term infusion (RR, 0.50; 95% CI, 0.26-0.96). Data for other specific infections were not available. The available evidence from mainly nonrandomized studies suggests that extended or continuous infusion of carbapenems or piperacillin/tazobactam was associated with lower mortality. Well-designed randomized controlled trials are warranted to confirm these findings before such approaches become widely used.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lodise, T. P., Lomaestro, B., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510590 · Cited by 527
Paul, M., Benuri-Silbiger, I., Soares-Weiser, K., & Leibovici, L. (2004) · BMJ · doi:10.1136/bmj.38028.520995.63 · Cited by 466
Safdar, N., Handelsman, J., & Maki, D. G. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01108-9 · Cited by 417
Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408
Prevention of Resistance: A Goal for Dose Selection for Antimicrobial Agents
Drusano, G. L. (2003) · Clinical Infectious Diseases · doi:10.1086/344653 · Cited by 356
Roberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp139 · Cited by 347
A systematic review on clinical benefits of continuous administration of β-lactam antibiotics*
Roberts, J. A., Webb, S., Paterson, D., Ho, K. M., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181a0054d · Cited by 225
Carbapenems: a potent class of antibiotics
Nicolau, D. P. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.1.23 · Cited by 213
Paul, M., Yahav, D., Fraser, A., & Leibovici, L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki448 · Cited by 202
Zanetti, G., Bally, F., Greub, G., Garbino, J., Kinge, T., Lew, D., Romand, J.-A., Bille, J., Aymon, D., Stratchounski, L., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3442-3447.2003 · Cited by 190
Kasiakou, S. K., Sermaides, G. J., Michalopoulos, A., Soteriades, E. S., & Falagas, M. E. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70218-8 · Cited by 189
Self-citationRoberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Dalley, A. J., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.008 · Cited by 188
Lorente, L., Lorenzo, L., Martín, M. M., Jiménez, A., & Mora, M. L. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g467 · Cited by 181
Treatment of Acinetobacter infections
Michalopoulos, A., & Falagas, M. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003596350 · Cited by 180
Self-citationSakka, S. G., Glauner, A. K., Bulitta, J. B., Kinzig-Schippers, M., Pfister, W., Drusano, G. L., & Sörgel, F. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01318-06 · Cited by 159
Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination
Gin, A. S., Dilay, L., Karlowsky, J. A., Walkty, A. J., Rubinstein, E., & Zhanel, G. G. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.3.365 · Cited by 153
Continuous infusion of β-lactam antibiotics in severe infections: a review of its role
Roberts, J. A., Paratz, J., Paratz, E., Krueger, W. A., & Lipman, J. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.02.002 · Cited by 150
Furno, P., Bucaneve, G., & Favero, A. D. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00241-4 · Cited by 150
Jaruratanasirikul, S., Sriwiriyajan, S., & Punyo, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1337-1339.2005 · Cited by 149
Lau, W. K. K., Mercer, D., Itani, K. M. F., Nicolau, D. P., Kuti, J. L., Mansfield, D. L., & Dana, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00329-06 · Cited by 139
Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance
Peterson, L. R. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01238.x · Cited by 129
Lorente, L., Jiménez, A., Martin, M. M. I. D. O., Iribarren, J. L., Jiménez, J. J., & Mora, M. L. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.10.025 · Cited by 127
Grant, E. M., Kuti, J. L., Nicolau, D. P., Nightingale, C. H., & Quintiliani, R. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.7.471.33665 · Cited by 126
Continuous infusion versus intermittent administration of meropenem in critically ill patients
Thalhammer, F., Traunmüller, F., Menyawi, I. E., Frass, M., Hollenstein, U., Locker, G. J., Stoiser, B., Staudinger, T., Thalhammer-Scherrer, R., & Burgmann, H. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.4.523 · Cited by 125
Rafati, M. R., Rouini, M. R., Mojtahedzadeh, M., Najafi, A., Tavakoli, H., Gholami, K., & Fazeli, M. R. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.02.020 · Cited by 120
Lodise, T. P., Lomaestro, B. M., Rodvold, K. A., Danziger, L. H., & Drusano, G. L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4718-4724.2004 · Cited by 116
Li, C., Kuti, J. L., Nightingale, C. H., Mansfield, D. L., Dana, A., & Nicolau, D. P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki243 · Cited by 113
Krueger, W. A., Bulitta, J. B., Kinzig‐Schippers, M., Landersdorfer, C. B., Holzgrabe, U., Naber, K. G., Drusano, G. L., & Sörgel, F. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1881-1889.2005 · Cited by 105
Yost, R. J., Cappelletty, D. M., & RECEIPT Study Group (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.8.767 · Cited by 90
Optimal Meropenem Concentrations To Treat Multidrug-Resistant Pseudomonas aeruginosa Septic Shock
Taccone, F. S., COTTON, F. J., Roisin, S., Vincent, J., & Jacobs, F. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06389-11 · Cited by 88
Tamma, P. D., Putcha, N., Suh, Y. D., Arendonk, K. J. V., & Rinke, M. L. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-181 · Cited by 88
Pharmacokinetics of piperacillin–tazobactam: intermittent dosing versus continuous infusion
Buck, C., Bertram, N., Ackermann, T., Sauerbruch, T., Derendorf, H., & Paar, W. D. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.08.012 · Cited by 86
Paul, M., Yahav, D., Bivas, A., Fraser, A., & Leibovici, L. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005197.pub3 · Cited by 84
Monotherapy or Combination Therapy? The Pseudomonas aeruginosa Conundrum
Traugott, K. A., Echevarria, K. L., Maxwell, P. R., Green, K., & Lewis, J. S. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.6.598 · Cited by 80
The Use of Carbapenems in the Treatment of Serious Infections
Baughman, R. P. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609335660 · Cited by 57
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Frosco, M., Lawrence, L. E., & Barrett, J. F. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.12.1951 · Cited by 54
Wang, D. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.09.012 · Cited by 41
Perrott, J. L., Mabasa, V. H., & Ensom, M. H. H. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m339 · Cited by 38
Florea, N. R., Kotapati, S., Kuti, J. L., Geissler, E. C., Nightingale, C. H., & Nicolau, D. P. (2003) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/60.22.2321 · Cited by 38
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia
Siempos, I. Ι., Vardakas, K. Z., Manta, K. G., & Falagas, M. E. (2007) · European Respiratory Journal · doi:10.1183/09031936.00080206 · Cited by 37
Self-citationVardakas, K. Z., Mavros, M. N., Roussos, N. S., & Falagas, M. E. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.12.011 · Cited by 34
Self-citationMah, G. T., Mabasa, V. H., Chow, I., & Ensom, M. H. H. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q378 · Cited by 26
Kikuchi, E., Kikuchi, J., Nasuhara, Y., Oizumi, S., Ishizaka, A., & Nishimura, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01578-08 · Cited by 22
Pédeboscq, S., Dubau, B., Frappier, S., Hernandez, V., Veyssières, D., Winnock, S., & Pometan, J.-P. (2001) · Pathologie Biologie · doi:10.1016/s0369-8114(01)00210-3 · Cited by 12
Okimoto, N., Ishiga, M., Nanba, F., Kibayashi, T., Kishimoto, M., Kurihara, T., Honda, Y., Asaoka, N., & Tamada, S. (2009) · PubMed · Cited by 7
Research works printed but not linked: 10
- Thiem, 2011, Elderly patients with community-acquired pneumonia: optimal treatment strategies, Drugs Aging, 28, 519, 10.2165/11591980-000000000-00000 · doi:10.2165/11591980-000000000-00000
- Dow, 2011, Retrospective study of prolonged versus intermittent infusion piperacillin-tazobactam and meropenem in intensive care unit patients at an academic medical center, Infect Dis Clin Pract, 19, 413, 10.1097/IPC.0b013e31822e9bf5 · doi:10.1097/ipc.0b013e31822e9bf5
- Itabashi, 2007, Clinical efficacy of prolonged (4 hour) drip infusion of meropenem against severe pneumonia, Japan J Antibiot, 60, 161
- Patel, 2009, Outcomes of extended infusion piperacillin/tazobactam for documented gram-negative infections, Diagn Microbiol Infect Dis, 64, 236, 10.1016/j.diagmicrobio.2009.03.002 · doi:10.1016/j.diagmicrobio.2009.03.002
- Kojika, 2005, A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time, Jpn J Antibiot, 58, 452
- Pedeboscq, 2001, Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin, Pathol Biol (Paris), 49, 540
- Falagas, 2006, Cure of persistent, post-appendectomy Klebsiella pneumoniae septicaemia with continuous intravenous administration of meropenem, Scand J Infect Dis, 38, 807, 10.1080/00365540500504125 · doi:10.1080/00365540500504125
- Kim, 2009, Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia, Clin Ther, 31, 2765, 10.1016/j.clinthera.2009.11.026 · doi:10.1016/j.clinthera.2009.11.026
- Lee, 2010, Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation, Diagn Microbiol Infect Dis, 68, 251, 10.1016/j.diagmicrobio.2010.06.012 · doi:10.1016/j.diagmicrobio.2010.06.012
- Bliziotis, 2011, Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia, PLoS One, 6, e26470, 10.1371/journal.pone.0026470 · doi:10.1371/journal.pone.0026470
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw118 · Cited by 3,061
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges
Wong, D., Nielsen, T. B., Bonomo, R. A., Pantapalangkoor, P., Luna, B., & Spellberg, B. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-16 · Cited by 1,170
Tunkel, A. R., Hasbun, R., Bhimraj, A., Byers, K., Kaplan, S. L., Scheld, W. M., van de Beek, D., Bleck, T. P., Garton, H. J. L., & Zunt, J. R. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw861 · Cited by 1,067
Metadata
- Authors
- Falagas, M. E., Tansarli, G. S., Ikawa, K., & Vardakas, K. Z.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-10-16
- Volume
- 56
- Issue
- 2
- Pages
- 272-282
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2150263213
- Cited by
- 283
- References
- 45
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.